Search Results for: Avandia

Featured Stories
Fracking Boom Changing Way of Life in Pennsylvania’s Northern Tier

Fracking Boom Changing Way of Life in Pennsylvania's Northern Tier

In just a few years, the impact of hydraulic fracturing (fracking) drilling on northeastern Pennsylvania is hard to miss. Thousands of natural gas wells have been opened in that area specifically in the last five years as companies look to exploit the vast Marcellus shale formation about two miles below the ...

Read More

Metal-on-Metal Hip Implant Lawyer Takes Issue with Statements Made by DePuy Orthpaedics Official During FDA Meeting

Metal-on-Metal Hip Implant Lawyer Takes Issue with Statements Made by DePuy Orthpaedics Official During FDA Meeting

An attorney with a national law firm that represents victims of alleged metal-on-metal hip implant injuries has expressed dismay at some statements made last week regarding the regulation of all-metal hip replacement devices by an official with DePuy Orthopaedics. According to Daniel Burke, Senior Litigation Counsel at Parker ...

Read More

First DePuy ASR Hip Implant Lawsuits Head to Trial in December, January

First DePuy ASR Hip Implant Lawsuits Head to Trial in December, January

The first trials involving lawsuits filed against DePuy Orthopaedics by recipients of its recalled ASR Hip Implants will begin later this year, and early next year. The first is slated to start on December 3, 2012 in state court in Las Vegas, Nevada. A second DePuy ASR hip implant lawsuit ...

Read More

West Virginia Man Claims Metal-on-Metal DePuy Pinnacle Hip Replacement Led to Pain, Elevated Cobalt Levels

West Virginia Man Claims Metal-on-Metal DePuy Pinnacle Hip Replacement Led to Pain, Elevated Cobalt Levels

A West Virginia man fitted with a metal-on-metal version of DePuy Orthopaedics’ Pinnacle Hip Implant System has filed suit against the company and its parent, Johnson & Johnson, alleging the device caused him to suffer pain and elevated cobalt levels. The Plaintiff is being represented by the national law ...

Read More

Pradaxa Named in Most FDA Adverse Event Reports for Deaths, Hemorrhage, Kidney Failure and Stroke

Pradaxa Named in Most FDA Adverse Event Reports for Deaths, Hemorrhage, Kidney Failure and Stroke

The controversial blood thinner, Pradaxa, surpassed all other drugs monitored by the U.S. Food & Drug Administration (FDA) in adverse event reports made to the agency last year. According to the Institute for Safe Medicine Practices’ (ISMP) latest QuarterWatch report, Pradaxa also topped the list for reports of deaths, ...

Read More

Federal DePuy ASR Hip Implant Trials Likely to Start This Year

Federal DePuy ASR Hip Implant Trials Likely to Start This Year

It looks as though the first trials in the DePuy ASR hip implant multidistrict litigation could begin sometime later this year. According to a report from Bloomberg News, during a status conference held yesterday in Florida, attorneys for both plaintiffs and the defense told U.S. District Judge David Katz that ...

Read More

Study Finds Plavix May Only Benefit Smokers

Study Finds Plavix May Only Benefit Smokers

An emerging study finds that blood thinner Plavix may only benefit smokers. Plavix (clopidogrel) is prescribed for the prevention of blood clots and heart attacks, and has been linked to serious side effects, including the heart attacks and strokes it is supposed to prevent, gastrointestinal and cerebral bleeding, bleeding ulcers, ...

Read More

Johnson & Johnson’s Ethicon Division to End Sales of Gynecare Prolift, Three Other Transvaginal Mesh Devices

Johnson & Johnson’s Ethicon Division to End Sales of Gynecare Prolift, Three Other Transvaginal Mesh Devices

Johnson & Johnson’s Ethicon Inc. division revealed yesterday that it will end sales of its Gynecare Prolift device and three other transvaginal mesh products. The plan to stop selling the four products was set forth in a letter filed by the company in the Ethicon transvaginal mesh multidistrict litigation ...

Read More

Medtronic Settles Charges Over Kickbacks To Doctors

Medical device giant, Medtronic Inc., is settling charges over kickbacks to doctors. The firms just agreed to pay $23.5 million to settle claims it paid physicians kickbacks in exchange for their use of its pacemakers and defibrillators, according to a U.S. Justice Department announcement yesterday. The company was accused of seeking ...

Read More

Majority of Metal-on-Metal Hip Implant Failures Occur within Two Years, Study Finds

Majority of Metal-on-Metal Hip Implant Failures Occur within Two Years, Study Finds

A newly published metal-on-metal hip replacement study is reporting that the majority of failures occur early, within two years of surgery. The study, published in the journal Orthopedics, is just the latest to indicate that close follow-up of metal-on-metal hip implant patients is warranted.

Read More

FDA Reviews Heart Failure Risks Associated with Diabetes Drugs Onglyza and Kombiglyze

onglyza-and-kombiiglyze-cardiac-risks

In a Drug Safety Communication issued Tuesday, the U.S. Food and Drug Administration (FDA) said that it has requested clinical trial data to analyze the association between heart failure and saxagliptin, a Type 2 diabetes drug marketed as Onglyza and … Continue reading

Posted in Legal News |

Despite Increasing Injury Reports, Mounting Lawsuits, and Growing Data, FDA, EMA Will Not Confirm Increased Pancreatic Side Effects with Incretin Drugs

increting_drugs_side_effects

The U.S. Food and Drug Administration (FDA) agrees with the European Medicines Agency (EMA) that prevailing data concerning Type 2 diabetes medications in the class known as glucagonlike peptide-1 (GLP-1)-based diabetes therapies, do not confirm increased pancreatic side effect risks, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Glaxo Agrees to $229 Million Avandia Settlement with Eight States

glaxo_avandia_settlement

In response to lawsuits brought by eight U.S. states, drug maker, GlaxoSmithKline, has agreed to pay hundreds of millions of dollars to settle actions over diabetes medication, Avandia (rosiglitazone). The drug maker announced it would pay $229 million and, in … Continue reading

Posted in Avandia, Pharmaceuticals |

Texas Man Files Lawsuit Alleging Actos Caused His Bladder Cancer

texas_actos_bladder_cancer_lawsuit

A Texas man has filed a lawsuit in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-02229) alleging that the diabetes drug Actos is to blame for his bladder cancer. This case is one of thousands … Continue reading

Posted in Actos, Health Concerns, Pharmaceuticals |

Drug Maker, Roche, Ceases New Type 2 Diabetes Drug Testing Over Safety Risks

roche_diabetes_drugs

Drug maker, Roche, just announced it has stopped development of a diabetes drug that is in the same class as the Type 2 diabetes drugs Actos and Avandia. The move, according to The New York Times, could raise safety concerns … Continue reading

Posted in Actos, Avandia, Pharmaceuticals |

Diabetes Drug Fails to Cut Heart Risks, Clinical Trial Shows

onglyza_heart_health_ineffective

In a large clinical trial, Onglyza (saxagliptin), a Type 2 diabetes medication, failed to reduce the risk of heart attacks and related disease compared with a placebo. But the drug, co-marketed by Bristol-Myers Squibb and AstraZeneca, did not increase cardiovascular … Continue reading

Posted in Avandia, Health Concerns, Pharmaceuticals |

Type 2 Diabetes Medication Risks Examined in Journal Review

type2_diabetes_drugs

Incretin mimetics, a class of Type 2 diabetes drugs, are sparking debate and renewing concerns about health risks, especially to the pancreas. In fact, a piece published in the journal BMJ, states that the drugs, which include Byetta and Januvia, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

New Lawsuit Alleges Actos Caused Arizona Man’s Bladder Cancer

Arizona_Actos_Bladder_Cancer

An Arizona man who took the diabetes drug Actos (pioglitazone) for several years has filed a lawsuit alleging that the drug caused his bladder cancer. The lawsuit further alleges that Takeda Pharmaceuticals, the drug’s manufacturer, was aware of the risk … Continue reading

Posted in Actos, Health Concerns, Pharmaceuticals |

FDA Recommends Easing Avandia Restrictions

FDA_Avandia_Restrictions

A vote at the conclusion of a two-day meeting of United States health advisors ended with a recommendation to ease current market restrictions on Type 2 diabetes drug, Avandia, which is marketed by GlaxoSmithKline. The U.S. Food and Drug Administration … Continue reading

Posted in Avandia, Legal News, Pharmaceuticals |

FDA Reconsidering its Stance on Avandia

FDA-Avandia-Restrictions

In an unprecedented move, the U.S. Food and Drug Administration is reopening the matter involving Type 2 diabetes drug, Avandia, which is marketed by GlaxoSmithKline. Avandia belongs to a class of diabetes drugs called thiazolidinediones that lower blood sugar by … Continue reading

Posted in Avandia, Pharmaceuticals |

© 2005-2014 Parker Waichman LLP ®. All Rights Reserved.